JP2006515310A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515310A5
JP2006515310A5 JP2004565816A JP2004565816A JP2006515310A5 JP 2006515310 A5 JP2006515310 A5 JP 2006515310A5 JP 2004565816 A JP2004565816 A JP 2004565816A JP 2004565816 A JP2004565816 A JP 2004565816A JP 2006515310 A5 JP2006515310 A5 JP 2006515310A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
dihydroisoindol
pharmaceutically acceptable
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004565816A
Other languages
English (en)
Japanese (ja)
Other versions
JP5269281B2 (ja
JP2006515310A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/041568 external-priority patent/WO2004060313A2/en
Publication of JP2006515310A publication Critical patent/JP2006515310A/ja
Publication of JP2006515310A5 publication Critical patent/JP2006515310A5/ja
Application granted granted Critical
Publication of JP5269281B2 publication Critical patent/JP5269281B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004565816A 2002-12-30 2003-12-29 フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用 Expired - Fee Related JP5269281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43697502P 2002-12-30 2002-12-30
US60/436,975 2002-12-30
PCT/US2003/041568 WO2004060313A2 (en) 2002-12-30 2003-12-29 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013026432A Division JP2013151497A (ja) 2002-12-30 2013-02-14 フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用

Publications (3)

Publication Number Publication Date
JP2006515310A JP2006515310A (ja) 2006-05-25
JP2006515310A5 true JP2006515310A5 (cg-RX-API-DMAC7.html) 2006-12-07
JP5269281B2 JP5269281B2 (ja) 2013-08-21

Family

ID=32713116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004565816A Expired - Fee Related JP5269281B2 (ja) 2002-12-30 2003-12-29 フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用
JP2013026432A Pending JP2013151497A (ja) 2002-12-30 2013-02-14 フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013026432A Pending JP2013151497A (ja) 2002-12-30 2013-02-14 フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用

Country Status (17)

Country Link
US (4) US7173058B2 (cg-RX-API-DMAC7.html)
EP (1) EP1587474B1 (cg-RX-API-DMAC7.html)
JP (2) JP5269281B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050090435A (cg-RX-API-DMAC7.html)
CN (1) CN1802353A (cg-RX-API-DMAC7.html)
AT (1) ATE449081T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003303511B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317885A (cg-RX-API-DMAC7.html)
CA (1) CA2511843C (cg-RX-API-DMAC7.html)
DE (1) DE60330187D1 (cg-RX-API-DMAC7.html)
ES (1) ES2333220T3 (cg-RX-API-DMAC7.html)
IL (1) IL169439A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006998A (cg-RX-API-DMAC7.html)
NZ (1) NZ541487A (cg-RX-API-DMAC7.html)
TW (1) TW200418779A (cg-RX-API-DMAC7.html)
WO (1) WO2004060313A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505308B (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI990180A7 (fi) * 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
KR20050090435A (ko) 2002-12-30 2005-09-13 셀진 코포레이션 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도
BRPI0408223A (pt) * 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
EP1660449B1 (en) * 2003-08-28 2009-11-18 Novartis AG Aminopropanol derivatives
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
WO2006022762A1 (en) * 2004-08-02 2006-03-02 Muhammed Majeed Compositions and methods for the management of hyperproliferative dermatological conditions
WO2006028963A2 (en) 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
JP4575097B2 (ja) * 2004-09-28 2010-11-04 株式会社エヌ・ティ・ティ・ドコモ 電子メール課金システム及び電子メール課金方法
MX2007006992A (es) * 2004-12-13 2007-08-03 Celgene Corp Composiciones que comprenden moduladores pde4 y su uso para el tratamiento o prevencion de la inflamacion de las vias aereas.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8450336B2 (en) 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2691987C (en) * 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PT2231640E (pt) * 2008-01-24 2012-08-23 Merck Patent Gmbh Derivados beta-aminoácido para o tratamento de diabetes
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010030345A2 (en) * 2008-09-10 2010-03-18 Celgene Corporation Processes for the preparation of aminosulfone compounds
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY160002A (en) 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
CA2765015C (en) 2009-06-18 2020-05-05 Concert Pharmaceuticals, Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
DK2473172T3 (en) * 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US8415485B2 (en) * 2009-10-09 2013-04-09 Celgene Corporation Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
US8846623B2 (en) * 2010-10-25 2014-09-30 Academia Sinica Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102558022B (zh) * 2010-12-22 2016-06-15 康塞特医药品有限公司 取代的异吲哚啉-1,3二酮衍生物
ES2673114T3 (es) * 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
AR090100A1 (es) 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015068142A2 (en) * 2013-11-11 2015-05-14 Cellworks Group, Inc. Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP3142663A1 (en) 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
CN105294533A (zh) * 2015-12-02 2016-02-03 宋彤云 一种治疗骨病的药物组合物
CN105503695A (zh) * 2016-01-16 2016-04-20 许兰兰 一种治疗糖尿病的药物组合物
CN105523922B (zh) * 2016-03-10 2017-12-29 聂红梅 一种罗氟司特中间体的制备方法
US11337964B2 (en) * 2017-02-28 2022-05-24 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, pharmaceutical composition and use thereof
CN107698484B (zh) * 2017-11-13 2020-05-19 广东中科药物研究有限公司 一种来那度胺的衍生物的制备方法与应用
CN110386893B (zh) * 2018-04-17 2025-07-11 天津合美医药科技有限公司 异吲哚衍生物
CN110423213B (zh) * 2019-08-22 2021-06-04 上海英诺富成生物科技有限公司 一种阿普斯特衍生物及其制备方法与应用
CN114790164B (zh) * 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298389C (cg-RX-API-DMAC7.html)
DD298389A5 (de) 1990-03-06 1992-02-20 Bayer Aktiengesellschaft,De Basische dihydropyridine verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
ES2196592T3 (es) 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
JP2003525203A (ja) * 1999-03-22 2003-08-26 ダーウィン・ディスカバリー・リミテッド ヒドロキサムおよびカルボン酸誘導体
AU4249700A (en) * 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative
US6316472B1 (en) * 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
AU1481701A (en) 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU6196201A (en) 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
JP2004506709A (ja) 2000-08-22 2004-03-04 ビーエーエスエフ アクチェンゲゼルシャフト βケトエノールエステル類の製造方法
KR20050090435A (ko) * 2002-12-30 2005-09-13 셀진 코포레이션 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도
NZ542670A (en) * 2003-03-12 2008-11-28 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
BRPI0408223A (pt) * 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição

Similar Documents

Publication Publication Date Title
CA2511843A1 (en) Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
JP6931019B2 (ja) 多発性硬化症を処置するためのs1p受容体モジュレーター
JP2008508299A5 (cg-RX-API-DMAC7.html)
CN104884076B (zh) 利用了hmgb1片段的心肌梗塞的治疗方法
JP2020125349A5 (cg-RX-API-DMAC7.html)
US20150272874A1 (en) Pulmonary disease-specific therapeutic agent
JP2023106403A5 (cg-RX-API-DMAC7.html)
CN101820916A (zh) 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
JP2020097596A5 (cg-RX-API-DMAC7.html)
RU2006128426A (ru) Производные тиофенав в качестве ингибиторов снк 1
WO2018082587A1 (zh) Hedgehog通路抑制剂在治疗纤维化疾病中的应用
JP2023506787A (ja) Parp阻害薬と組み合わせたatr阻害薬の使用
JP2020531463A5 (cg-RX-API-DMAC7.html)
JP2015187114A (ja) Parpインヒビターとの組合せ療法
JP2024546095A5 (cg-RX-API-DMAC7.html)
JP2006516643A5 (cg-RX-API-DMAC7.html)
JP2009502777A5 (cg-RX-API-DMAC7.html)
JPH1087484A5 (cg-RX-API-DMAC7.html)
CN1400900A (zh) 含二氨基三氟甲基吡啶衍生物的消化系统疾病治疗药或预防药
JP2023543993A5 (cg-RX-API-DMAC7.html)
JP2008542290A (ja) 皮膚狼瘡の治療又は予防のための4−[(シクロプロパンカルボニルアミノ)メチル]−2−(2,6−ジオキソピペリジン−3−イル)イソインドール−1,3−ジオンの使用方法及び組成物
JP2025509613A (ja) がん治療のためのMetAP2阻害剤を含む組み合わせ
CN1396827A (zh) 含二氨基三氟甲基吡啶衍生物的肺功能不全治疗药或预防药
JPH1067662A5 (cg-RX-API-DMAC7.html)